This review examines the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs), medications approved for type 2 diabetes and obesity now being investigated for eating disorders through their modulation of metabolic and reward pathways. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.